Chronic pelvic pain syndrome and semen quality of Korean men in their fourth decade.
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common  condition that adversely affects men across a wide range of ages. A number of  pharmacologic and nonpharmacologic therapies for CP/CPPS have been  investigated. Our study aimed to evaluate the prevalence of CPPS in Korean men  in their thirties and to investigate the effect of CPPS and medical treatment  on semen quality. Of 314 men with prostatitis, 74 patients with CPPS class  IIIA (23.6%) were eligible for the study; these patients underwent combined  α-blocker and cyclo-oxygenase 2 inhibitor therapy. These 74 men were  prospectively studied at a medical center in Seoul, Korea. A number of  parameters, including ejaculations per month, semen variables, and the levels  of hormones (such as follicle-stimulating hormone, estradiol [E(2)],  luteinizing hormone [LH], testosterone, and prolactin) were evaluated. The  mean number of ejaculations per month, the mean number of daily hours spent  sitting at work, smoking, body mass index, LH and E(2) levels, and  semen parameters all showed significant differences (P < .0001)  between the study patients and the controls. The combined regimen was  effective in improving all aspects of semen quality except morphology  (P < .05). CPPS class IIIA, which is notably prevalent among  Korean men in the fourth decade of life, affects semen quality and poses a  challenge to fertility. Proper treatment of CPPS class IIIA results in  improved semen quality. Men with CPPS therefore require proper evaluation and  treatment by andrologists/urologists before planning a natural conception.
Andrology Unit, Center for Reproductive Medicine, Zaii Urological Institute, Zaii Medical Center, Seoul, Korea.
Jae Sang
JS
Byun
Tae Ki
TK
Yoon
Hong Woo
HW
Rhee
Jin Hong
JH
Kim
Jun Shik
JS
Shin
Hong Seok
HS
Kim
Chong Won
CW
Bak
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D044466:Asian People; D001578:Benzopyrans / Q000627:therapeutic use; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D059350:Chronic Pain / Q000097:blood / Q000208:ethnology* / Q000473:pathology / Q000503:physiopathology; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D004542:Ejaculation; D004958:Estradiol / Q000097:blood; D043373:Follicle Stimulating Hormone, Human / Q000097:blood; D006801:Humans; D008019:Life Style; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D015999:Multivariate Analysis; D017699:Pelvic Pain / Q000097:blood / Q000208:ethnology* / Q000473:pathology / Q000503:physiopathology; D015995:Prevalence; D011388:Prolactin / Q000097:blood; D011422:Propionates / Q000627:therapeutic use; D011446:Prospective Studies; D011472:Prostatitis / Q000097:blood / Q000208:ethnology* / Q000473:pathology / Q000503:physiopathology; D011799:Quinazolines / Q000627:therapeutic use; D056910:Republic of Korea / Q000453:epidemiology; D018570:Risk Assessment; D012307:Risk Factors; D055101:Semen Analysis; D012737:Sex Factors; D013094:Spermatozoa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D013739:Testosterone / Q000097:blood
D058668:Adrenergic alpha-1 Receptor Antagonists; D001578:Benzopyrans; D052246:Cyclooxygenase 2 Inhibitors; D043373:Follicle Stimulating Hormone, Human; D011422:Propionates; D011799:Quinazolines; C043940:pyranoprofen; D013739:Testosterone; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; C047638:alfuzosin